Defunct Company
Total Trials
7
As Lead Sponsor
As Collaborator
0
Total Enrollment
315
NCT01141257
Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug
Phase: Phase 1
Role: Lead Sponsor
Start: May 31, 2010
Completion: Sep 30, 2011
NCT02340572
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080
Start: Nov 30, 2014
Completion: Aug 31, 2015
NCT02754167
Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
Phase: Phase 1/2
Start: Jun 6, 2016
Completion: Dec 31, 2017
NCT03330561
PRS-343 in HER2-Positive Solid Tumors
Start: Sep 13, 2017
Completion: Dec 1, 2023
NCT03325621
Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
Start: Sep 30, 2017
Completion: Jun 30, 2019
NCT03650348
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Start: Aug 21, 2018
Completion: Aug 11, 2022
NCT05190445
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Phase: Phase 2
Start: Nov 1, 2021
Completion: Feb 1, 2023